Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

Investing.com — 周四，H.C. Wainwright重申了对Alnylam Pharmaceuticals (NASDAQ: ALNY )的"买入"评级和500.00美元的目标价，较当前266.83美元的价格有87%的上涨空间。根据 InvestingPro 数据，分析师对该股票保持看涨共识，目标价格范围从206美元到500美元不等。该公司分析师Patrick ...

The approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...

Fierce Healthcare says the incident — in which patient data was reportedly stolen from servers sometime after Jan. 22 — has not yet been announced by Oracle Health but was reported Friday in an ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.